Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts
Authors:
- Raffael NachbagauerRNRaffael Nachbagauer
- Bruno SalaunBSBruno Salaun
- Daniel StadlbauerDSDaniel Stadlbauer
- Mohammad A. BehzadiMBMohammad A. Behzadi
- Damien FrielDFDamien Friel
- Arvind RajabhathorARArvind Rajabhathor
- Angela ChoiACAngela Choi
- Randy A. AlbrechtRARandy A. Albrecht
- Muriel DeboisMDMuriel Debois
- Adolfo García-SastreAGAdolfo García-Sastre
- Ronan N. RouxelRRRonan N. Rouxel
- Weina SunWSWeina Sun
Open Access
- 6 December 2019
- journal article
- research article
- Published by Springer Nature in npj Vaccines
- Vol. 4 (1) , 1-12
Abstract
Licensed influenza virus vaccines target the head domain of the hemagglutinin (HA) glycoprotein which undergoes constant antigenic drift. The highly conserved HA stalk domain is an attractive target to increase immunologic breadth required for universal influenza virus vaccines. We tested the hypothesis that immunization with a pandemic influenza virus vaccine boosts pre-existing anti-stalk antibodies. We used chimeric cH6/1, full length H2 and H18 HA antigens in an ELISA to measure anti-stalk antibodies in recipients participating in clinical trials of A/H1N1, A/H5N1 and A/H9N2 vaccines. The vaccines induced high titers of anti-H1 stalk antibodies in adults and children, with higher titers elicited by AS03-adjuvanted vaccines. We also observed cross-reactivity to H2 and H18 HAs. The A/H9N2 vaccine elicited plasmablast and memory B-cell responses. Post-vaccination serum from vaccinees protected mice against lethal challenge with cH6/1N5 and cH5/3N4 viruses. These findings support the concept of a chimeric HA stalk-based universal influenza virus vaccine. clinicaltrials.gov: NCT02415842.Keywords
This publication has 47 references indexed in Scilit:
- Adjuvants and Immunization Strategies to Induce Influenza Virus Hemagglutinin Stalk AntibodiesPLOS ONE, 2013
- A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccineBMC Infectious Diseases, 2012
- A Carboxy-Terminal Trimerization Domain Stabilizes Conformational Epitopes on the Stalk Domain of Soluble Recombinant Hemagglutinin SubstratesPLOS ONE, 2012
- A Pan-H1 Anti-Hemagglutinin Monoclonal Antibody with Potent Broad-Spectrum EfficacyIn VivoJournal of Virology, 2012
- Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 virusesProceedings of the National Academy of Sciences, 2012
- Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsionExpert Review of Vaccines, 2012
- Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infectionJournal of Experimental Medicine, 2011
- Antibodies against conserved antigens provide opportunities for reform in influenza vaccine designFrontiers in Immunology, 2011
- Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk DomainmBio, 2010
- Rapid cloning of high-affinity human monoclonal antibodies against influenza virusNature, 2008